Deals

Relmada dumps depression asset after slew of phase 3 failures

The biotech has terminated the license agreement for esmethadone, months after canceling two phase 3 trials that were not expected to hit their goals.

Darren Incorvaia Jul 11, 2025 12:12pm

Glowing puzzle piece fitting into puzzle

Eolas regains opioid use disorder drug abandoned by AstraZeneca

Jul 10, 2025 9:33am

Three blocks displaying from left to right a person a handshake and another person

AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer

Jul 10, 2025 9:01am

Novartis inks $175M option deal for Sironax’s BBB tech

Jul 9, 2025 10:29am

reshuffle pipeline target reorganize shift change

AstraZeneca’s Alexion pens $825M AAV capsid pact with JCR

Jul 9, 2025 4:52am

Concentra extends biotech shopping spree by collecting Cargo

Jul 8, 2025 9:28am